Retatrutide(RT)
5mg*10vials
$75.00 USD
Skip to product information
Retatrutide(RT)
$75.00 USD
Description
What Is Retatrutide (RT) Peptide?
In the evolving landscape of metabolic peptides, Retatrutide (RT) has emerged as a groundbreaking triple-agonist peptide, renowned for its powerful glycemic control, appetite regulation, and superior weight management effects by targeting three key metabolic receptors simultaneously. Unlike single or dual-action peptides, Retatrutide delivers comprehensive metabolic support, making it a top choice for those seeking to address obesity, type 2 diabetes, and optimize overall metabolic health. If you’re new to Retatrutide, let’s break down its basics, scientific background, and how it works to transform metabolic wellness.
1. Basic Information: Full Name, Abbreviation and Molecular Formula
Retatrutide is commonly known by its abbreviation RT, with the research designation LY3437943. It is a synthetic 39-amino-acid triple-receptor agonist peptide engineered with a C20 fatty diacid moiety to enhance stability and extend half-life to approximately 6 days, supporting convenient once-weekly administration. Its amino acid sequence is:
Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-α-Me-Leu-Leu-Asp-Lys-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.
The molecular formula is C₂₂₁H₃₄₂N₄₆O₆₈, with a molecular weight of approximately 4731 Da (4.73 kDa). As a highly stable, lipidated peptide, it is easily synthesized, purified, and formulated for research and wellness applications.
2. Scientific Research Progress of Retatrutide (RT) Peptide
Research on Retatrutide began with Eli Lilly’s efforts to develop a next-generation metabolic therapy, building on the success of GLP-1 (semaglutide) and dual GLP-1/GIP (tirzepatide) agonists. Preclinical studies in the 2010s confirmed its unique ability to simultaneously activate GLP-1, GIP, and glucagon receptors (Triple G agonism)—a first-in-class mechanism that addresses metabolic dysfunction through three complementary pathways.
Initial Phase 2 clinical trials (2021–2023) in obese and type 2 diabetes patients yielded transformative results: 48-week treatment with Retatrutide 12 mg achieved up to 24.2% body weight reduction, surpassing semaglutide (~15%) and tirzepatide (~22.5%). In 2026, Phase 3 trial (TRANSCEND-T2D-1) data published in The Lancet validated its efficacy: 40-week treatment reduced HbA1c by up to 2.0% and body weight by 16.8% (36.6 lbs) in type 2 diabetes patients, with no weight loss plateau observedEli Lilly ....
Recent research has expanded its potential applications. Preclinical studies in PMC journals demonstrate Retatrutide’s ability to inhibit tumor growth and enhance chemotherapy efficacy in obese triple-negative breast cancer (TNBC) by regulating YAP signaling and glycosylation pathwaysPMC. Additional studies highlight its benefits for non-alcoholic fatty liver disease (NAFLD), cardiovascular risk reduction, and metabolic syndrome management. While still under FDA review (not yet approved for clinical use), its favorable safety profile (mild gastrointestinal side effects: nausea, diarrhea) and unprecedented efficacy have positioned it as the most promising metabolic peptide in late-stage development柳叶刀Th....
3. Biological Action Mechanism of Retatrutide (RT) Peptide
Retatrutide exerts its powerful metabolic effects through three synergistic receptor pathways, working in harmony to regulate glucose, appetite, and energy expenditure—surpassing the limitations of single/dual agonists. Its mechanisms are well-documented in preclinical and clinical research:
- GLP-1 Receptor Activation: Binds to GLP-1 receptors in the pancreas, brain, and gut, driving glucose-dependent insulin secretion, suppressing glucagon (high blood sugar hormone), slowing gastric emptying, and reducing appetite via hypothalamic signaling. This core pathway delivers robust glycemic control and initial weight loss.
- GIP Receptor Activation: Complementary to GLP-1, GIP receptor activation enhances insulin secretion, improves metabolic efficiency, and modulates central hunger signals—amplifying weight loss and glycemic benefits beyond single GLP-1 agonists.
- Glucagon Receptor Activation (Key Differentiator): The unique third pathway that sets Retatrutide apart. It promotes hepatic fat oxidation, increases basal metabolic rate (BMR), and elevates energy expenditure, directly reducing liver fat (NAFLD) and driving superior weight loss by burning stored fat—without the hyperglycemic risk, offset by GLP-1 activity.
- Synergistic Metabolic Benefits: Combined triple agonism optimizes body composition (reducing fat mass while preserving lean muscle), improves lipid profiles (lower triglycerides, higher HDL), and reduces inflammation—supporting long-term metabolic health and reducing cardiovascular risk.
In summary, Retatrutide (RT) is a revolutionary, science-backed triple-agonist peptide with a well-defined mechanism of action and robust clinical research foundation. Its unparalleled ability to control blood sugar, suppress appetite, burn fat, and optimize metabolic health makes it the most advanced peptide for obesity and type 2 diabetes management. With its stable structure, long half-life, high purity, and exceptional efficacy, Retatrutide has become the most sought-after metabolic peptide in the global wellness and research markets.
Care
To maintain the beauty and integrity of your purchase, we recommend treating it with care. Simple maintenance practices, such as gentle washing and proper storage, can effectively preserve the longevity of your favorites. We encourage you to refer to the care instructions included with each item, designed to help you keep your purchase in top condition.
Design
Our dedication to excellence extends beyond materials; it encompasses the artistry and craftsmanship illustrated in every piece we create.